Article Details
Retrieved on: 2021-08-20 12:31:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Key Points. The FDA recently rejected AstraZeneca and FibroGen's roxadustat for the treatment of anemia in patients with chronic kidney disease. Even if ...
Article found on: www.fool.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here